Is Wegovy as Good as Mounjaro? What the Clinical Evidence Shows

Is Wegovy as good as Mounjaro? It is one of the most frequently asked questions by people choosing between the two leading weight loss injections in the UK. The honest answer is that both are clinically proven, MHRA-approved treatments that produce significant weight loss results, but they are not equivalent. Head-to-head clinical data, individual response variation, and practical considerations around cost, tolerability, and availability all shape which treatment is the better choice for any given person. This guide examines the evidence honestly and without bias. If you would like help deciding which treatment suits your situation, book an online consultation with Pills2U and explore our weight loss treatment options.

What the Head-to-Head Data Shows

The SURMOUNT-5 trial published in 2024 was the first large-scale randomised controlled trial to directly compare tirzepatide (Mounjaro) against semaglutide 2.4mg (Wegovy) in adults with obesity. The results showed that participants on tirzepatide lost an average of 20.2 percent of body weight over 72 weeks compared to 13.7 percent for semaglutide. The difference was statistically significant and consistent across subgroups.

This represents a meaningful clinical difference rather than a marginal one, and it explains why many prescribers and patients have moved toward tirzepatide as the preferred first option when the clinical criteria are met. However, trial averages do not tell the whole story of individual patient experience.

Efficacy Comparison at a Glance

Where Wegovy Still Has the Edge

Despite Mounjaro’s stronger average efficacy, Wegovy retains genuine advantages in certain areas that matter clinically and practically.

Wegovy has been available for longer in the UK and internationally, which means there is a larger body of real-world prescribing data and post-market safety surveillance. This longer track record is meaningful for clinicians assessing long-term safety in broader patient populations beyond trial participants.

Wegovy also has established cardiovascular outcome data from the SELECT trial, which demonstrated a 20 percent reduction in major adverse cardiovascular events in people with obesity and existing cardiovascular disease. This positions Wegovy as a treatment with benefits extending beyond weight loss for specific patient groups, a consideration that may influence prescriber choice for patients with relevant cardiac history.

For people considering the safety profile of Wegovy in more detail, our guide on Wegovy side effects covers what to expect. To understand the safety evidence for Mounjaro in parallel, our is Mounjaro safe guide reviews the clinical data in detail.

When Wegovy Might Be the Better Choice

• ◎
  You have an established history of cardiovascular disease and the SELECT trial outcomes data is clinically relevant to your case
• ◎
  Your prescriber has more experience with semaglutide and is more confident managing its dose escalation and side effects
• ◎
  You have tried Mounjaro and found the side effects more disruptive than the appetite benefit, and want to explore whether semaglutide suits your physiology better
• ◎
  Access or availability issues mean Wegovy is more readily available through your preferred provider at the time of prescribing
• ◎
  Your individual response to semaglutide turns out to be stronger than the trial average, which is entirely possible given the variation in individual outcomes

For NHS guidance on both treatments within the broader obesity management context, the NHS obesity treatment guidance provides useful background on the clinical criteria and prescribing landscape in the UK.

Frequently Asked Questions About Wegovy vs Mounjaro

Is Wegovy as effective as Mounjaro for weight loss?

On average, Mounjaro produces greater weight loss in clinical trials including the head-to-head SURMOUNT-5 comparison. However, individual responses vary considerably and some people achieve results on Wegovy that match or exceed what Mounjaro trials show on average.

Does Wegovy have any advantages over Mounjaro?

Yes. Wegovy has a longer real-world prescribing history and established cardiovascular outcome data from the SELECT trial. For patients with existing cardiovascular disease, Wegovy currently has more specific supporting evidence for cardiac risk reduction.

Can I switch from Wegovy to Mounjaro if I am not getting good results?

Yes, under prescriber guidance. Switching between treatments is clinically possible and sometimes appropriate. The dose at which you start on the new treatment will be assessed by your prescriber based on your history with the previous medication.

Are the side effects different between Wegovy and Mounjaro?

The side effect profiles overlap significantly as both act on the GLP-1 pathway. The most common side effects including nausea, diarrhoea, and constipation occur with both. Some people report a different intensity of specific symptoms between the two, though this varies individually rather than following a consistent pattern.

Is one safer than the other?

Both are MHRA-approved medications that have passed regulatory safety review. Neither is considered categorically safer than the other. Individual suitability based on health history, existing conditions, and contraindications is what determines which is the safer choice for a specific patient.